Biorestorative Therapies (BRTX)
(Delayed Data from NSDQ)
$1.73 USD
+0.04 (2.37%)
Updated Oct 15, 2024 03:46 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Biorestorative Therapies, Inc. [BRTX]
Reports for Purchase
Showing records 1 - 20 ( 52 total )
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Recent Presentation at IFATS Outlines Progress With ThermoStem Development
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 9, 2024
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
2Q24: Enrolling cLDD Trial by YE24, Biocosmeceutical Biz Alive, BADSC Deal?
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
5th Japan Patent and 4 U.S. Patents for ThermoStem, Near-Term Deal Likely
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Real Near-Term Potential to Monetize ThermoStem BADSC Program
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
1Q24: Phase 2 cLDD Trial Should Enroll By YE24, Biocosmeceutical Biz Active
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Developing Novel Exosome-Based Weight Loss Therapeutic
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Signs Commercial Deal with Medical Aesthetics Technology Company Cartessa
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Ongoing BRTX-100 Trial Can Use Sham Injection Control Rather Than Saline
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Galen To Help Speed Phase 2 Enrollment, Which Should Finish By YE24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Recent Encouraging Blinded Preliminary Phase 2 BRTX-100 Data in cLDD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Encouraging, Albeit Blinded, Preliminary Phase 2 BRTX-100 Data in cLDD
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Biorestorative Therapies, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare: HC Opportunities Conference in NYC on October 12th
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S